Ascenta Capital is a company.
Key people at Ascenta Capital.
Ascenta Capital was founded by Lorence Kim (Co-founder and Managing Partner).
Ascenta Capital was founded by Lorence Kim (Co-founder and Managing Partner).
Ascenta Capital is a venture capital firm founded in 2023, specializing in early-stage biotech investments, particularly platform companies in Phase 1 and Phase 2 clinical trials that develop multiple medicines from a single core technology.[1][2][4] Its mission centers on advancing innovative medicines to patients by providing concentrated capital, strategic guidance, and operational support in clinical, regulatory, manufacturing, and capital strategy, with a patient-first philosophy.[1][2] The firm targets diversified biotech pipelines across therapeutic areas like oncology, autoimmune diseases, infectious diseases, and rare diseases, emphasizing collaborative investments alongside top-tier co-investors.[1][4] In October 2025, Ascenta closed its inaugural $325 million Fund I after leading or co-leading six syndicates and deploying over $100 million, solidifying its role in the biotech startup ecosystem by backing high-potential platforms at pivotal early clinical moments.[1]
Ascenta Capital was established in 2023 in Florida (with a Delaware base) by co-founders and managing partners Evan Rachlin, M.D., and Lorence Kim, M.D., both former senior leaders at Moderna.[1][4][5] Rachlin, previously Head of Strategy at Moderna (reporting to the CEO), Managing Director at Blackstone Life Sciences, Principal at Bain Capital Ventures, and early roles at McKinsey and Pfizer, brings expertise in portfolio strategy, financings, and biotech operations.[1][4] Kim, Moderna's CFO from 2014-2020 (raising $4 billion and advancing 24 candidates including the COVID-19 vaccine), was also a Venture Partner at Third Rock Ventures, co-founder of ElevAAte Biotech, and a Goldman Sachs managing director co-heading U.S. biotech investment banking.[1][4] Their shared Moderna experience—amid its historic financings and pipeline growth—sparked Ascenta's focus on platform biotechs, evolving from operational leadership to a selective VC model.[1][2] Early traction included six investments pre-Fund I close in September/October 2025.[1][5]
Ascenta rides the biotech renaissance, fueled by converging advances in biology, chemistry, life science tech, data analytics, talent, and capital, enabling rapid translation of preclinical science into clinical proof-of-concept for unmet patient needs.[2] Timing is ideal post-2025 Fund I, amid a shift toward platform companies that de-risk pipelines in a high-interest-rate environment favoring diversified bets over single-asset plays.[1] Market forces like unprecedented funding for early clinical biotechs (e.g., Moderna's playbook) and demand for precision medicines in oncology, autoimmune, and rare diseases amplify its edge.[1][4] Ascenta influences the ecosystem by bridging operational biotech experience with VC, nurturing platforms that could yield blockbusters (echoing KEYTRUDA, Velcade, Dupixent), and fostering East Asian leadership via Kim's ElevAAte.[1][2][4]
With Fund I deployed and a Phase 1/2 platform focus, Ascenta is primed to lead more syndicates in multi-asset biotechs, leveraging 2026+ tailwinds like AI-driven drug discovery and precision medicine.[1][2] Trends shaping its path include biotech's rebound via data/AI integration and capital efficiency, potentially expanding to immuno-oncology or RNA platforms per portfolio hints.[1][4] Its influence may grow through board seats, exits like Moderna's, and team expansions, evolving from niche player to biotech powerhouse—transforming scientific foundations into patient-impacting medicines, true to its patient-centered origins.[2]
Key people at Ascenta Capital.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 5, 2026 | Angitia Biopharmaceuticals | $130.0M Series D | Frazier Life Sciences, Venrock Healthcare Capital Partners | 3H Health Investment, Bain Capital Life Sciences, Biotechnology Value Fund, BlackRock, Elikon Venture, Hillhouse Investment, Janus Henderson Investors, Legend Capital, Logos Capital, Morningside, OrbiMed, RA Capital Management, TF Capital, Wellington Management, Yonghua Capital |
